Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Insulin plus SGLT2 inhibitor or metformin in newly diagnosed type 2 diabetes
ChiCTR2600116249Phase 4Not yet recruiting
- Sponsor
- Zhu Xianyi Memorial Hospital
- Start
- Jan 2026
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4 trial of human insulin, metformin and empagliflozin in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by Zhu Xianyi Memorial Hospital. Primary endpoint: HbA1c. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
human insulinmetforminempagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on ChiCTR2600116249.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600116249.